Fibrate therapy in the management of diabetic dyslipidemia: There is no ACCORD to be found

Current Atherosclerosis Reports

Volumn 12, Issue 5, 2010, Pages 331-335

  Toth, Peter P ^a  

^a Sterling Rock Falls Clinic ^*  (United States)

Author keywords

Atherogenic dyslipidemia; Diabetes mellitus; Fibrate; High density lipoprotein; Insulin resistance; Residual risk; Triglyceride

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LUNG EMBOLISM; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; INSULIN RESISTANCE; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 77956261925     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0126-3     Document Type: Review

References (34)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. JG Robinson B Smith N Maheshwari H Schrott 2005 Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 1855 1862 10.1016/j.jacc.2005.05.085 1:CAS:528: DC%2BD2MXht1SrtbzF 16286171
3. PP Toth C Cadman 2007 Implications of recent statin trials for primary care practice J Clin Lipidol 1 182 190 10.1016/j.jacl.2007.05.004
4. AR Sharrett CM Ballantyne SA Coady, et al. 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 1108 1113 10.1161/hc3501.095214 1:CAS:528:DC%2BD3MXotlWgur0%3D 11535564
5. LS Jonsdottir N Sigfusson V Gudnason, et al. 2002 Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study J Cardiovasc Risk 9 67 76 10.1097/00043798-200204000-00001 12006913
6. N Sarwar J Danesh G Eiriksdottir, et al. 2007 Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies Circulation 115 450 458 10.1161/CIRCULATIONAHA. 106.637793 1:CAS:528:DC%2BD2sXnvF2ntQ%3D%3D 17190864 This is the largest meta-analysis to date demonstrating an independent relationship between serum levels of TG and risk for CHD
7. S Bansal JE Buring N Rifai, et al. 2007 Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 309 316 10.1001/jama.298.3.309 1:CAS:528:DC%2BD2sXotValtb0%3D 17635891 This observational study establishes the potential importance of evaluating nonfasting serum TG when estimating risk for CHD in women
8. BG Nordestgaard M Benn P Schnohr A Tybjaerg-Hansen 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 299 308 10.1001/jama.298.3.299 1:CAS:528:DC%2BD2sXotVWmsrk%3D 17635890
9. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 1988, 4(Suppl A):5A-10A.
10. Assmann G, Cullen P, Schulte H: The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998, 19(Suppl A):A2-A11.
11. PP Toth 2001 High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects Dis Mon 47 369 416 10.1067/mda.2001.118859 1:STN:280:DC%2BD3MrisVWmtQ%3D%3D 11571478
12. Standards of medical care in diabetes. Diabetes Care 2005, 28(Suppl 1):S4-S36.
13. HM Colhoun DJ Betteridge PN Durrington, et al. 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 696 10.1016/S0140-6736(04)16895-5 1:CAS:528:DC%2BD2cXmvFWltrY%3D 15325833
14. PM Kearney L Blackwell R Collins, et al. 2008 Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125 10.1016/S0140-6736(08) 60761-8 1:STN:280:DC%2BD1c%2FjvVWmsg%3D%3D 18191683
15. B Staels JC Fruchart 2005 Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2460 2470 10.2337/diabetes.54.8.2460 1:CAS:528:DC%2BD2MXnt1ynt7Y%3D 16046315
16. J Auwerx K Schoonjans JC Fruchart B Staels 1996 Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR Atherosclerosis 124 Suppl S29 37 10.1016/0021-9150(96)05854-6 1:CAS:528:DyaK28XjvFCru7k%3D 8831913
17. D Zhu SH Ganji VS Kamanna ML Kashyap 2002 Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells Atherosclerosis 164 221 228 10.1016/S0021-9150(02) 00060-6 1:CAS:528:DC%2BD38XmsVCrt7w%3D 12204791
18. G Chinetti-Gbaguidi E Rigamonti L Helin, et al. 2005 Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages J Lipid Res 46 2717 2725 10.1194/jlr.M500326-JLR200 1:CAS:528:DC%2BD2MXhtlWmsb7P 16162941
19. JC Fruchart B Staels P Duriez 2001 The role of fibric acids in atherosclerosis Curr Atheroscler Rep 3 83 92 10.1007/s11883-001-0015-x 1:STN:280:DC%2BD3Mvnt1Cnsg%3D%3D 11123853
20. P Delerive K De Bosscher S Besnard, et al. 1999 Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1 J Biol Chem 274 32048 32054 10.1074/jbc.274.45.32048 1:CAS:528:DyaK1MXnt12jt74%3D 10542237
21. JK Huttunen MH Frick OP Heinonen, et al. 1988 Helsinki Heart Study. New perspectives in the prevention of coronary heart disease Drugs 36 Suppl 3 32 36 10.2165/00003495-198800363-00009 3076118
22. SJ Robins 2001 Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial Am J Cardiol 88 19N 23N 10.1016/S0002-9149(01)02148-8 1:CAS:528:DC%2BD38XitlWgug%3D%3D 11788126
23. Bloomfield Rubins H, Davenport J, Babikian V, et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001, 103:2828-2833.
24. HB Rubins SJ Robins D Collins, et al. 2002 Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med 162 2597 2604 10.1001/archinte.162.22.2597 1:CAS:528:DC%2BD38Xpslens70%3D 12456232
25. SJ Robins HB Rubins FH Faas, et al. 2003 Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care 26 1513 1517 10.2337/diacare.26.5.1513 1:CAS:528:DC%2BD3sXjvVegsbs%3D 12716814
26. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
27. A Keech RJ Simes P Barter, et al. 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 1849 1861 10.1016/S0140-6736(05)67667-2 1:STN:280:DC%2BD2MnjtVCnsg%3D%3D 16310551
28. R Scott R O'Brien G Fulcher, et al. 2009 Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493 498 10.2337/dc08-1543 1:CAS:528:DC%2BD1MXjvVyqt7s%3D 18984774 This is a post hoc analysis of the FIELD trial demonstrating once again that fibrate therapy reduces risk for cardiovascular events in patients with hypertriglyceridemia and low HDL-C
29. MH Frick M Syvanne MS Nieminen, et al. 1997 Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group Circulation 96 2137 2143 1:CAS:528:DyaK2sXmvVKrsr4%3D 9337181
30. de Faire U, Ericsson CG, Grip L, et al.: Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17(Suppl F):37-42.
31. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
32. HN Ginsberg MB Elam LC Lovato, et al. 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563 1574 10.1056/NEJMoa1001282 20228404
33. E Bruckert M Baccara-Dinet F McCoy J Chapman 2005 High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 1927 1934 10.1185/030079905X74871 1:CAS:528:DC%2BD28XhtF2jurY%3D 16368042
34. MJ Jacobs T Kleisli JR Pio, et al. 2005 Prevalence and control of dyslipidemia among persons with diabetes in the United States Diabetes Res Clin Pract 70 263 269 10.1016/j.diabres.2005.03.032 15890427